Citations 2
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas
Kumar, Shaji , Rajkumar, S. Vincent , Chng, Wee Joo , Engelhardt, Monika, Gonsalves, Wilson, Hungria, Vânia , Hillengaß, Jens , Jevremovic, Dragan, Lonial, Sagar, Elias, K. , Manier, Salomon , Martin, T, Mateos, María‐Victoria , Mian, Hira , Munshi, Nikhil C. , Rasche, Leo , Sborov, Douglas W. , Kastritis, Efstathios , Kumar, Shaji K , Rajkumar, S Vincent , Chng, Wee Joo , Costa, Luciano J , Hungria, Vania , Hillengass, Jens , Katodritou, Eirini , Kristinsson, Sigurdur Y , Ludwig, Heinz , McCarthy, Phillip , Mai, Elias K , Manier, Salomon , Mateos, María-Victoria , Mian, Hira , Mikhael, Joseph R , Moreau, Philippe , Munshi, Nikhil C , Paiva, Bruno , Pawlyn, Charlotte , Rasche, Leo , Richter, Joshua , San-Miguel, Jesus , Sborov, Douglas W , Usmani, Saad , Dimopoulos, Meletios A , Zamagni, Elena , Kastritis, Efstathios , Costa, Luciano J. , Engelhardt, Monika , Gonsalves, Wilson I. , Jevremović, Dragan , Katodritou, Eirini , Lonial, Sagar , Ludwig, Heinz , McCarthy, Philip L. , Mıkhael, Joseph , Moreau, Philippe , Paiva, Bruno , Pawlyn, Charlotte , Richter, Joshua , Miguel, Jesús F. San , Usmani, Saad Z. , Dimopoulos, Meletios Α. , Zamagni, Elena
Journal of Clinical Oncology | July 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
Solitary plasmacytomas (SPs) are rare localized tumors of clonal plasma cells, either in the bone (solitary bone plasmacytoma) or in soft tissue/extraosseous (extramedullary) with either no or with minimal bone marrow (BM) infiltration (<10% clonal plasma cells by immunohistochemistry) and no evidence of systemic involvement or myeloma defining events. Approximately 50% of SPs will progress to symptomatic myeloma within 5 years after initial definitive local radiotherapy. Increased availability of improved diagnostic and monitoring tools has increased the sensitivity of detection of additional lesions and marrow involvement and has implications for the follow-up strategy after treatment. Thus, the definitions and requirements for the diagnosis and follow-up of SPs are evolving. The diagnosis of SP requires the careful exclusion of multiple myeloma (MM) that would require systemic therapy, by using all the available methods to detect systemic disease (advanced imaging, sensitive BM assessment methods, blood and urine tests). Local radiotherapy remains the mainstay of therapy, and despite the availability of innovative drugs for MM, the clinical benefit of systemic therapy currently remains poorly defined. The International Myeloma Working Group provides here updated recommendations for the diagnosis, evaluation, treatment, and response assessment of patients with SPs, incorporating recent data and advances in diagnostic tools.
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Ghobrial, Irene M. , Kumar, Shaji , Mateos, María‐Victoria , Bergsagel, P. Leif , Chesi, Marta , Dhodapkar, Madhav V. , Getz, Gad , Manier, Salomon , Nuvolone, Mario , O’Donnell, Elizabeth , Sklavenitis‐Pistofidis, Romanos , Sperling, Adam S. , Vassiliou, George S. , Munshi, Nikhil C. , Bergsagel, P. Leif , Gormley, Nicole , Kumar, Shaji K , Mateos, María-Victoria , Chesi, Marta , Dhodapkar, Madhav V , Getz, Gad , Kastritis, Efstathios , Kristinsson, Sigurdur Y , Martinez-Climent, Jose Angel , Manier, Salomon , Marinac, Catherine R , Maura, Francesco , Morgan, Gareth J , Davies, Faith E , Nadeem, Omar , Nuvolone, Mario , Paiva, Bruno , O'Donnell, Elizabeth , Prosper, Felipe , Shah, Urvi A , Sklavenitis-Pistofidis, Romanos , Sperling, Adam S , Munshi, Nikhil C , Castle, Philip E , Anderson, Kenneth C , San-Miguel, Jesus , Ghobrial, Irene M , Gormley, Nicole , Dispenzieri, Angela , Fonseca, Rafaël , Kastritis, Efstathios , Martinez‐Climent, José A. , Marinac, Catherine R. , Maura, Francesco , Morgan, Gareth J. , Davies, Faith E. , Nadeem, Omar , Paiva, Bruno , Prósper, Felipe , Shah, Urvi A. , Anderson, Kenneth C. , Miguel, Jesús F. San
Blood Cancer Discovery | March 5, 2024 | Volume: 5 | Issue: 3 | Pages: 146-152
Summary: While the current approach to precursor hematologic conditions is to “watch and wait,” this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit–risk assessment.